{"id":"W4311621329","doi":"10.1136/ard-2022-222543","title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eli Lilly Japan; Genentech; Idorsia Pharmaceuticals; Teijin Pharma; Taichung Veterans General Hospital; Assistance publique-Hôpitaux de Paris; Chugai Pharmaceutical; National Yang-Ming University; Duke Clinical Research Institute; Astellas Pharma; Eisai; Mitsubishi Tanabe Pharma Corporation; Medicines Company; Regado Biosciences; St. Jude Medical; Nippon Shinyaku; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Belvoir Media Group; Boehringer Ingelheim Japan; Novo Nordisk; MyoKardia; Daiichi Sankyo Europe; Gilead Sciences; Bristol-Myers Squibb; Cleveland Clinic; Actelion Pharmaceuticals; Ministry of Science and Technology, Taiwan; Moderna; Pfizer; Biogen; HLS Therapeutics; GlaxoSmithKline; CSL Behring; Eli Lilly and Company; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Tofacitinib; Rheumatoid arthritis; Open label; Malignancy; Internal medicine; Dermatology; Randomized controlled trial; TNF inhibitor; Clinical trial; Arthritis; Oncology; Adalimumab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00428865,0.001379096,0.003363368,0.0003435115,0.000365069,0.001827011,0.0007248976,0.001665736,0.004517633],"category_scores_gemma":[0.006578257,0.0005071549,0.003683985,0.0005755402,0.0009981389,0.00106265,0.0004282976,0.002617907,0.0005456211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007843075,"about_ca_system_score_gemma":0.0009376885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001304581,"about_ca_topic_score_gemma":0.002270964,"domain_scores_codex":[0.9972458,0.001829542,0.0002594228,0.0002980376,0.000187617,0.0001797174],"domain_scores_gemma":[0.9958396,0.00142899,0.001689074,0.0002785535,0.0002461285,0.0005177104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9840646,0.001039078,0.001586286,0.000957159,0.002332497,0.00002223285,0.00003062669,0.0001124172,0.0004136159,0.00003887074,0.0003272578,0.009075272],"study_design_scores_gemma":[0.959457,0.03088813,0.005513539,0.0001402449,0.002827299,0.00005262661,0.00003604949,0.0002769997,0.0001898542,0.0001194168,0.0004831098,0.00001587303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667957,0.02576843,0.0006195253,0.000912662,0.000610379,0.001464305,0.001823526,0.00007788048,0.001927578],"genre_scores_gemma":[0.9867538,0.006914982,0.0008222315,0.0006619197,0.0008800846,0.001331081,0.001400848,0.00001674876,0.001218295],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004517633,"threshold_uncertainty_score":0.02268076,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05098159510434724,"score_gpt":0.3178714133574589,"score_spread":0.2668898182531116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}